



Source

Anti-Bevacizumab Antibody (AY9) is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.

Clone

AY9

Species

Mouse

Isotype

Mouse IgG1/kappa

Antibody Type

Hybridoma Monoclonal

Reactivity

Human

Immunogen

Bevacizumab.

Specificity

Recognizes Bevacizumab specifically.

Application

Application	Recommended Usage
ELISA	20-10000 ng/mL

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A purified/ Protein G purified

Formulation

Lyophilized from 0.22 μ m filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- 4-8°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.

SDS-PAGE




Anti-Bevacizumab Antibody (AY9) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Discounts, Gifts,
and more!







Bioactivity-ELISA



Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 1 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9 ng/mL (QC tested).




Demonstration of the specificity of Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9) to the bevacizumab.



Measured by its neutralizing ability in a functional ELISA. Immobilized bevacizumab at 2 µg/mL (100 µL/well) can bind pre-mixed Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9) and Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a inhibition rate of 62%.

Bioactivity-MSD



Anti-Bevacizumab Antibodies bridging MSD for Anti-Drug Antibody (ADA) assay development. Added the mix solution (biotinylated Bevacizumab at 5 µg/mL, SULFO-Bevacizumab at 5 µg/mL and increasing concentrations of

Discounts, Gifts, and more!



Anti-Bevacizumab Antibody (AY9) (recommended for ADA assay)


Catalog # BEB-Y9



BIOSYSTEMS
Acro
Surprise Inside!

Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9, 100% human serum).
Detection was performed using MSD Assay with a sensitivity of 0.97 ng/mL.

Bioactivity-SPR



Anti-Bevacizumab Antibody (AY9) (mouse IgG1, Cat. No. BEB-Y9) captured on CM5 chip via anti-mouse antibodies surface, can bind human bevacizumab with an affinity constant of 1.92 nM.

Background

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

Clinical and Translational Updates

Discounts, Gifts,
and more!



➤ www.acrobiosystems.com

11/19/2024